Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesenchymal stem cells for progressive multiple sclerosis
2020-002373-95Phase 2Active
- Sponsor
- Haukeland University Hospital
- Start
- Aug 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of mesenchymal stem cells in multiple sclerosis (MS) (2 arms), sponsored by Haukeland University Hospital. Primary endpoint: Primary endpoint: change in combined evoked potentials at 6 months. Started Aug 2020; status: active.
02
Drugs
mesenchymal stem cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2020-002373-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002373-95.